Enhertu
Active Ingredient(s): Fam-trastuzumab Deruxtecan-nxkiFDA Approved: * December 20, 2019
Pharm Company: * DAIICHI SANKYO
Category: Cancer
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan).[5][6] It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma.[6][7] Trastuzumab binds to and blocks signaling through epidermal growth factor... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Enhertu 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 65597-406
Labeler:
Daiichi Sankyo Inc.
